Tags

Type your tag names separated by a space and hit enter

Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention.
Ann Agric Environ Med. 2016 12 23; 23(4):537-541.AA

Abstract

Polycystic ovary syndrome is a disorder which affects 5-10% of women in reproductive age. PCOS is a cause of hyperandrogenism, menstrual disorders and infertility. The most common clinical symptoms are hirsutism, acne and obesity. Patients often suffer from metabolic disorders: insulin resistance, hyperinsulinemia, dislipidemia, leading to atherosclerosis and others irregularities of the metabolic syndrome. Patients are in the high risk group for cardiovascular diseases (CVD) development because of the metabolic abnormalities. Obesity is observed in 35-60% of women with PCOS. Lean women with PCOS are also exposed to a greater risk of glucose intolerance development and abnormalities in lipid profile than women without PCOS with comparable BMI. Adipocytes are the source of many compounds of the paracrine and endocrine activity. Some of them are also markers and mediators of inflammation. Increased levels of proinflammatory cytokines in blood can promote atherosclerosis and cardiovascular disease. Markers: IL-18, TNF, IL-6 and hs-CRP are often elevated in patients with polycystic ovary syndrome. An increase in inflammatory markers may be an early indicator of the risk of developing insulin resistance and atherosclerosis, and may become a useful prognostic and therapeutic tool for monitoring patients with PCOS: lean and those with overweight and obesity. Assessment of the concentrations of inflammatory markers may become a very useful test in evaluating the risk of developing atherosclerosis and cardiovascular disease, long before their clinical manifestation. It will also allow for the appropriate prophylaxis.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland.

Nawrocka Rutkowska J

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland.

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland.

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland.

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland.

MeSH

Cardiovascular DiseasesFemaleHumansInflammationPolycystic Ovary Syndrome

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

28030919

Citation

Marciniak, Aleksandra, et al. "Cardiovascular System Diseases in Patients With Polycystic Ovary Syndrome - the Role of Inflammation Process in This Pathology and Possibility of Early Diagnosis and Prevention." Annals of Agricultural and Environmental Medicine : AAEM, vol. 23, no. 4, 2016, pp. 537-541.

Marciniak A, Nawrocka Rutkowska J, Brodowska A, et al. Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 2016;23(4):537-541.

Marciniak, A., Nawrocka Rutkowska, J., Brodowska, A., Wiśniewska, B., & Starczewski, A. (2016). Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Annals of Agricultural and Environmental Medicine : AAEM, 23(4), 537-541. https://doi.org/10.5604/12321966.1226842

Marciniak A, et al. Cardiovascular System Diseases in Patients With Polycystic Ovary Syndrome - the Role of Inflammation Process in This Pathology and Possibility of Early Diagnosis and Prevention. Ann Agric Environ Med. 2016 12 23;23(4):537-541. PubMed PMID: 28030919.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. AU - Marciniak,Aleksandra, AU - Nawrocka Rutkowska,Jolanta, AU - Brodowska,Agnieszka, AU - Wiśniewska,Berenika, AU - Starczewski,Andrzej, PY - 2016/12/30/entrez PY - 2016/12/30/pubmed PY - 2017/1/14/medline SP - 537 EP - 541 JF - Annals of agricultural and environmental medicine : AAEM JO - Ann Agric Environ Med VL - 23 IS - 4 N2 - Polycystic ovary syndrome is a disorder which affects 5-10% of women in reproductive age. PCOS is a cause of hyperandrogenism, menstrual disorders and infertility. The most common clinical symptoms are hirsutism, acne and obesity. Patients often suffer from metabolic disorders: insulin resistance, hyperinsulinemia, dislipidemia, leading to atherosclerosis and others irregularities of the metabolic syndrome. Patients are in the high risk group for cardiovascular diseases (CVD) development because of the metabolic abnormalities. Obesity is observed in 35-60% of women with PCOS. Lean women with PCOS are also exposed to a greater risk of glucose intolerance development and abnormalities in lipid profile than women without PCOS with comparable BMI. Adipocytes are the source of many compounds of the paracrine and endocrine activity. Some of them are also markers and mediators of inflammation. Increased levels of proinflammatory cytokines in blood can promote atherosclerosis and cardiovascular disease. Markers: IL-18, TNF, IL-6 and hs-CRP are often elevated in patients with polycystic ovary syndrome. An increase in inflammatory markers may be an early indicator of the risk of developing insulin resistance and atherosclerosis, and may become a useful prognostic and therapeutic tool for monitoring patients with PCOS: lean and those with overweight and obesity. Assessment of the concentrations of inflammatory markers may become a very useful test in evaluating the risk of developing atherosclerosis and cardiovascular disease, long before their clinical manifestation. It will also allow for the appropriate prophylaxis. SN - 1898-2263 UR - https://www.unboundmedicine.com/medline/citation/28030919/Cardiovascular_system_diseases_in_patients_with_polycystic_ovary_syndrome___the_role_of_inflammation_process_in_this_pathology_and_possibility_of_early_diagnosis_and_prevention_ DB - PRIME DP - Unbound Medicine ER -